28 Results for "

autoimmune conditions

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "autoimmune conditions" in MCE Product Catalog:

Cat. No.: HY-P990206

Research Areas:  

Inflammation/Immunology

Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE) .
Cat. No.: HY-B1451R
CAS No.: 89396-94-1
Synonyms: TA-6366 (Standard)
Imidapril (hydrochloride) (Standard) is the analytical standard of Imidapril (hydrochloride). This product is intended for research and analytical applications. Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions .
Cat. No.: HY-B1451S
CAS No.: 1356017-30-5
Imidapril-d3 hydrochloride (TA-6366-d3) is the deuterium labeled Imidapril hydrochloride. Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions .
Cat. No.: HY-185144
CAS No.: 3104330-39-1
Target:  

CCR

Research Areas:  

Inflammation/Immunology

CCL17-IN-1 (Compound Ex.132) is a CCL17 secretion inhibitor with an EC50 of 0.2 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders .
Cat. No.: HY-185145
CAS No.: 3104330-35-7
Target:  

CCR

Research Areas:  

Inflammation/Immunology

CCL17-IN-2 (Compound Ex.128) is a CCL17 secretion inhibitor with an EC50 of 0.3 nM. CCL17-IN-1 can be used in the research of autoimmune diseases, dermatological conditions, and respiratory disorders .
Cat. No.: HY-119050
CAS No.: 749860-43-3
Target:  

CCR

Research Areas:  

Inflammation/Immunology

Anti-inflammatory agent 87 (compound 72) is a potential anti-inflammatory agent, whose precursor is an inhibitor targeting the binding of thymus and activation-regulated chemokine (TARC/CCL17) to Hut78 cells. Anti-inflammatory agent 87 can be used in the research of allergic diseases, autoimmune diseases, transplant rejection and other conditions .
Cat. No.: HY-184095
CAS No.: 3047739-67-0
Synonyms: Iptocigistatum
Research Areas:  

Inflammation/Immunology

Iptocigistat (Iptocigistatum) is a cyclic GMP-AMP synthase (cGAS) inhibitor. Iptocigistat prevents excessive immune responses. Iptocigistat can be used to study inflammation-related autoimmune diseases .
Cat. No.: HY-L237
317 compounds

Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.

MCE has cataloged 317 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.